How Might the Inflation Reduction Act influence Future Generic and Biosimilar Development and Adoption?
Monday, November 7, 2022
4:00 p.m. - 5:00 p.m.
The Inflation Reduction Act marks one of the most significant changes to federal drug reimbursement policy in the last 20 years. During this session, policy experts will provide a detailed review of the legislation’s changes and possible impacts on the pharmaceutical industry, provide an outlook on implementation processes and procedures, and discuss how these changes might impact future biosimilar and generic opportunities.
Moderator: Monét Stanford, PharmD
Director, Policy
John Brooks, JD
Partner, South Capitol
Shawn Brown
Vice President, Government Affairs, Lupin Pharmaceuticals
Tim Casey
Senior Director, Government Affairs & Policy, Fresenius Kabi USA
